Spruce Biosciences (SPRB) Projected to Post Earnings on Wednesday

Posted by ABMN Staff on Mar 10th, 2025

Spruce Biosciences (NASDAQ:SPRB – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $0.89 million for the quarter.

Spruce Biosciences Trading Down 1.7 %

Spruce Biosciences stock opened at $0.35 on Monday. Spruce Biosciences has a 52 week low of $0.34 and a 52 week high of $5.53. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.36 and a current ratio of 5.36. The firm has a market capitalization of $14.59 million, a PE ratio of -0.38 and a beta of 2.34. The business’s 50-day simple moving average is $0.39 and its 200-day simple moving average is $0.45.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on SPRB shares. Royal Bank of Canada reiterated a “sector perform” rating and issued a $1.50 price objective (down from $2.00) on shares of Spruce Biosciences in a research note on Wednesday, December 11th. Guggenheim restated a “neutral” rating on shares of Spruce Biosciences in a research report on Thursday, December 12th. JMP Securities reiterated a “market perform” rating and set a $3.00 target price on shares of Spruce Biosciences in a report on Wednesday, December 11th. HC Wainwright restated a “neutral” rating on shares of Spruce Biosciences in a research note on Monday, December 16th. Finally, Oppenheimer restated a “market perform” rating on shares of Spruce Biosciences in a research note on Wednesday, December 11th. Nine research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $2.38.

Check Out Our Latest Research Report on Spruce Biosciences

About Spruce Biosciences

(Get Free Report)

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.